Ftse Mib
35.143,06
-0,49%
DAX
20.214,79
-0,51%
S&P 500
5.833,90
-1,43%
NASDAQ
19.144,76
-1,72%
Bitcoin
94.997,59
2,79%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Qualigen Therapeutics Inc (QLGN) Qualigen Therapeutics Inc (QLGN) Notizie

Qualigen Therapeutics Inc

QLGN
4,0412
-0,1288 (-3,09%)
Ultimo aggiornamento: 18:26:11
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
26/12/202422:10EDGAR2Form 8-K - Current report
20/12/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
10/12/202420:27EDGAR2Form S-1 - General form for registration of securities under..
05/12/202415:00GLOBEQualigen Therapeutics Announces Regained Compliance with..
25/11/202423:00GLOBEUnivest Securities, LLC Announces Successful Closing of $5.1..
21/11/202423:10EDGAR2Form 8-K/A - Current report: [Amend]
21/11/202422:10EDGAR2Form 8-K - Current report
19/11/202415:00GLOBEQualigen Therapeutics Announces $4.5 Million Private..
14/11/202422:25EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/11/202423:10EDGAR2Form 8-K - Current report
08/11/202423:25EDGAR2Form 8-K - Current report
01/11/202421:55EDGAR2Form 8-K - Current report
01/11/202414:00GLOBEShares Expected to Begin Trading on Split-Adjusted Basis..
29/10/202421:05EDGAR2Form 8-K - Current report
24/10/202423:06EDGAR2Form S-1 - General form for registration of securities under..
22/10/202422:35EDGAR2Form 8-K - Current report
09/10/202422:10EDGAR2Form 8-K - Current report
09/10/202422:10EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
26/9/202423:10EDGAR2Form 8-K - Current report
26/9/202423:10GLOBEQualigen Therapeutics, Inc. Announces management changes.
20/9/202422:10EDGAR2Form 8-K - Current report
20/9/202415:00GLOBEQualigen Therapeutics, Inc. Received Extension from Nasdaq..
09/9/202423:15EDGAR2Form 8-K - Current report
06/9/202423:00GLOBEUnivest Securities, LLC Announces Closing of $3.46 Million..
06/9/202422:30GLOBEQualigen Therapeutics, Inc. Announces Closing of $3.47..
06/9/202421:46EDGAR2Form 424B4 - Prospectus [Rule 424(b)(4)]
05/9/202415:25EDGAR2Form 8-K - Current report
05/9/202415:00GLOBEQualigen Therapeutics, Inc. Announces Pricing of $3.46..
22/8/202422:41EDGAR2Form S-1/A - General form for registration of securities..
14/8/202422:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/8/202421:58EDGAR2Form S-1/A - General form for registration of securities..
07/8/202423:28EDGAR2Form S-1/A - General form for registration of securities..
05/8/202422:10EDGAR2Form 8-K - Current report
18/7/202423:00EDGAR2Form 8-K - Current report
15/7/202423:06EDGAR2Form 8-K - Current report
15/7/202412:15EDGAR2Form 8-K - Current report
11/7/202423:25EDGAR2Form 8-K - Current report
01/7/202414:00GLOBELifecore Biomedical Announces Cooperation Agreement with..
30/5/202422:00EDGAR2Form 8-K - Current report
30/5/202422:00GLOBEQualigen Therapeutics, Inc. Received Nasdaq Notice of a..
14/5/202422:05EDGAR2Form NT 10-Q - Notification of inability to timely file Form..
04/5/202402:59EDGAR2Form S-1/A - General form for registration of securities..
16/4/202413:00GLOBEMarizyme Enters Into Co-Development Agreement With Qualigen..
10/4/202414:00GLOBEQualigen Therapeutics' Novel Direct Pan-RAS Inhibitors..
09/4/202414:00GLOBEQualigen Therapeutics Announces Poster Featuring Positive..
27/2/202413:00EDGAR2Form 8-K - Current report
22/2/202422:10EDGAR2Form 8-K - Current report
Apertura: 4,25 Min: 3,90 Max: 4,25
Chiusura: 4,17

La tua Cronologia

NASDAQ
QLGN
Qualigen Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network